32 related articles for article (PubMed ID: 38436494)
1. Effects of meal type on the bioavailability of vutiglabridin, a novel anti-obesity agent, in healthy subjects.
Won H; Yoon DY; Lee S; Cho JY; Oh J; Jang IJ; Yoo SK; Yu KS
Clin Transl Sci; 2024 Mar; 17(3):e13744. PubMed ID: 38436494
[TBL] [Abstract][Full Text] [Related]
2. Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies.
Preskorn S; Ereshefsky L; Chiu YY; Poola N; Loebel A
Hum Psychopharmacol; 2013 Sep; 28(5):495-505. PubMed ID: 24014143
[TBL] [Abstract][Full Text] [Related]
3. Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects.
Kim HC; Yang E; Lee S; Oh J; Lee M; Lee C; Ha KS; Lee WS; Jang IJ; Yu KS
Invest New Drugs; 2024 Feb; 42(1):80-88. PubMed ID: 38099989
[TBL] [Abstract][Full Text] [Related]
4. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
[TBL] [Abstract][Full Text] [Related]
5. Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males.
Li J; Tan Y; Li K; Hui AM; Wu Z; Han P; Wei Z; Qiu J; Diao L; Wang X
Adv Ther; 2023 Mar; 40(3):1074-1086. PubMed ID: 36627544
[TBL] [Abstract][Full Text] [Related]
6. Effect of High-Fat Food on the Pharmacokinetic Profile and Safety of SAF-189s, an ALK/ROS1 Inhibitor, in Healthy Chinese Adults.
Qin H; Tan Y; Diao L; Hui AM; Wu Z; Zhou Y; Sun J; Xiang X; Qiu J; Hu W
Drugs R D; 2023 Dec; 23(4):465-473. PubMed ID: 37934354
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first-in-class, first-in-human study.
Na JY; Yoon DY; Yoo H; Lee S; Yu KS; Jang IJ; Yoo SK; Kim Y; Oh J
Clin Transl Sci; 2022 Nov; 15(11):2744-2757. PubMed ID: 36176051
[TBL] [Abstract][Full Text] [Related]
8. Effect of lipophilicity on drug distribution and elimination: Influence of obesity.
Bruno CD; Harmatz JS; Duan SX; Zhang Q; Chow CR; Greenblatt DJ
Br J Clin Pharmacol; 2021 Aug; 87(8):3197-3205. PubMed ID: 33450083
[TBL] [Abstract][Full Text] [Related]
9. Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity.
Choi LS; Jo IG; Kang KS; Im JH; Kim J; Kim J; Chung JW; Yoo SK
Int J Obes (Lond); 2021 Jan; 45(1):130-142. PubMed ID: 32943760
[TBL] [Abstract][Full Text] [Related]
10. Species Differences in Stereoselective Pharmacokinetics of HSG4112, A New Anti-Obesity Agent.
Bae IY; Choi MS; Ji YS; Yoo SK; Kim K; Yoo HH
Pharmaceutics; 2020 Feb; 12(2):. PubMed ID: 32028738
[TBL] [Abstract][Full Text] [Related]
11. Relationship between the effects of food on the pharmacokinetics of oral antineoplastic drugs and their physicochemical properties.
Omachi F; Kaneko M; Iijima R; Watanabe M; Itagaki F
J Pharm Health Care Sci; 2019; 5():26. PubMed ID: 31827876
[TBL] [Abstract][Full Text] [Related]
12. Obesity: global epidemiology and pathogenesis.
Blüher M
Nat Rev Endocrinol; 2019 May; 15(5):288-298. PubMed ID: 30814686
[TBL] [Abstract][Full Text] [Related]
13. Preserving Healthy Muscle during Weight Loss.
Cava E; Yeat NC; Mittendorfer B
Adv Nutr; 2017 May; 8(3):511-519. PubMed ID: 28507015
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
